Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major chronic liver disease affecting approximately 30% of the adult population worldwide. Progression from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), characterized by hepatocellular injury and inflammation, leads to rapid liver fibrosis, resulting in fatal complications such as cirrhosis and liver cancer.

Until now, the standard for confirming disease severity and fibrosis stage was percutaneous liver biopsy. However, biopsy involves risks such as pain, bleeding, and organ damage, and is subject to sampling errors depending on the site of tissue extraction. The area sampled by a needle is only about 1/50,000 of the entire liver, leading to significant inter-pathologist discrepancy. Furthermore, it was practically impossible for primary care providers to recommend liver biopsies as a screening test for the vast number of asymptomatic patients.

As drug development and clinical practice change rapidly, this bottleneck has become more pronounced. With targeted drugs, including resmetirom, receiving regulatory approval or entering late-stage clinical trials, the urgent need to identify patients who can directly benefit from treatment has grown. This provides the background for the desperate need for testing strategies that can safely identify patients using blood markers or imaging techniques instead of high-risk biopsies.

Key Findings

This analysis, published in the latest issue of The Lancet, shows that non-intensive tests (NITs) have moved beyond being mere supplementary tools to becoming the central axis for patient classification, referral pathway establishment, and prediction of treatment response. The core goal of clinical decision-making lies in accurately identifying patients with moderate fibrosis (≥F2) or advanced fibrosis (≥F3) who are likely to gain substantial benefits from drug therapy.

Researchers propose a multi-stage evaluation pathway that combines primary screening with precise interpretation. In the primary care stage, low-risk groups are quickly excluded using simple blood biomarkers, such as the Fibrosis-4 (FIB-4) index, which combines platelet count, age, and liver enzyme levels. Patients classified as intermediate or high risk at this stage proceed to the second stage, undergoing precision imaging tests such as vibration-controlled transient elastography (VCTE) or magnetic resonance elastography (MRE).

This stepwise combination of tests reduced the need for biopsies by 60% to as much as 80%, while maintaining an accuracy of over 85% in identifying patients with advanced fibrosis, which is a criterion for clinical trial eligibility. In particular, it significantly reduced the rate of unnecessary screening failures due to false positives during the clinical trial recruitment process. This effectively improved the efficiency of entering clinical protocols while ensuring patient safety.

It was also confirmed that the setting of absolute cut-off values for test results must be subdivided according to the patient's age and presence of diabetes. Elderly patients over 65 or patients with type 2 diabetes tend to show relatively higher FIB-4 scores due to baseline platelet counts or vascular stiffness. Researchers explain that adjusted criteria reflecting these clinical variables must be applied to reduce false positives and prevent unnecessary referrals to tertiary hospitals.

Implications and Outlook

This achievement will serve as a catalyst to fundamentally reshape the prescription environment for MASH drugs. In the past, due to the high barrier of confirmatory liver biopsy, the selection of candidates for drug administration was limited to specialists at university hospitals. Once an NIT-centered standard protocol is established, early intervention will become possible in primary care settings such as endocrinology, cardiology, and family medicine, which manage metabolic diseases.

However, challenges remain before full integration into clinical practice. While blood-based biomarkers are low-cost and highly accessible, they are susceptible to influence from acute inflammation or drug toxicity other than non-alcoholic fatty liver disease. Advanced imaging equipment like VCTE or MRE boasts high diagnostic accuracy, but its deployment in primary care is limited by high equipment costs and a lack of skilled personnel.

Additional verification is also required in the area of monitoring treatment response to determine whether fibrosis has actually improved after drug administration. Large-scale prospective cohort follow-up studies, which clarify the time lag between the rate of fibrosis tissue change and changes in blood biomarker levels, will lead to the completion of future disease management guidelines.